The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Abstract
Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.Methods In EMPOWER-Lung 1, a multicentre, open-label, global, phase 3 study, eligible patients recruited in 138 clinics from 24 countries (aged ≥18 years with histologically or cytologically confirmed advanced non-small-cell lung cancer, an Eastern Cooperative Oncology Group performance status of 0-1; never-smokers were ineligible) were randomly assigned (1:1) to cemiplimab 350 mg every 3 weeks or platinum-doublet chemotherapy. Crossover from chemotherapy to cemiplimab was allowed following disease progression. Primary endpoints were overall survival and progression-free survival per masked independent review committee. Primary endpoints were assessed in the intention-to-treat population and in a prespecified PD-L1 of at least 50% population (per US Food and Drug Administration request to the sponsor), which consisted of patients with PD-L1 of at least 50% per 22C3 assay done according to instructions for use. Adverse events were assessed in all patients who received at least one dose of the assigned treatment. This study is registered with ClinicalTrials.gov, NCT03088540 and is ongoing.Findings Between June 27, 2017 and Feb 27, 2020, 710 patients were randomly assigned (intention-to-treat population). In the PD-L1 of at least 50% population, which consisted of 563 patients, median overall survival was not reached (95% CI 17·9-not evaluable) with cemiplimab (n=283) versus 14·2 months (11·2-17·5) with chemotherapy (n=280; hazard ratio [HR] 0·57 [0·42-0·77]; p=0·0002). Median progression-free survival was 8·2 months (6·1-8·8) with cemiplimab versus 5·7 months (4·5-6·2) with chemotherapy (HR 0·54 [0·43-0·68]; p<0·0001). Significant improvements in overall survival and progression-free survival were also observed with cemiplimab in the intention-to-treat population despite a high crossover rate (74%). Grade 3-4 treatment-emergent adverse events occurred in 98 (28%) of 355 patients treated with cemiplimab and 135 (39%) of 342 patients treated with chemotherapy.Interpretation Cemiplimab monotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%, providing a potential new treatment option for this patient population.Funding Regeneron Pharmaceuticals and Sanofi.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It may result in better OS and PFS compared to platinum-based chemotherapy in patients with advanced NSCLC, indicating a possible new treatment option for these patients [51].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [51]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationRittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
Self-citationInterpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Cited by
Sorted by citations
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M., Beasley, M. B., Borczuk, A., Brambilla, E. M., Cooper, W. A., Đačić, S., Jain, D., Kerr, K. M., Lantuéjoul, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,656
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,127
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 726
Hendriks, L. E. L., Remón, J., Finn, C. F., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 690
Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 685
Socinski, M. A., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., Thomas, C. A., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.009 · Cited by 553
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L. P., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 547
Survival with Cemiplimab in Recurrent Cervical Cancer
Tewari, K. S., Monk, B. J., Vergote, I., Miller, A., de Melo, A. C., Kim, H.-S., Kim, Y. M., Lisyanskaya, A., Samouëlian, V., Lorusso, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112187 · Cited by 474
Self-citationJohnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00975 · Cited by 463
Advances in systemic therapy for non-small cell lung cancer
Miller, M., & Hanna, N. H. (2021) · BMJ · doi:10.1136/bmj.n2363 · Cited by 396
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
Mamdani, H. M., Matosevic, S., Khalid, A. B., Durm, G. A., & Jalal, S. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.823618 · Cited by 384
Recent advances in non-small cell lung cancer targeted therapy; an update review
Araghi, M., Mannani, R., Maleki, A. H., Hamidi, A., Rostami, S. M., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02990-y · Cited by 374
Ren, S., Chen, J., Xu, X., Jiang, T., Cheng, Y., Chen, G., Pan, Y., Fang, Y., Wang, Q., Huang, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.018 · Cited by 324
Gogishvili, M., Melkadze, T., Makharadze, T., Giorgadze, D., Dvorkin, M. V., Penkov, K., Лактионов, К. К., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01977-y · Cited by 319
Self-citationStratigos, A., Sekulić, A., Peris, K., Bechter, O. E., Prey, S., Kaatz, M., Lewis, K. D., Basset‐Séguin, N., Chang, A. L. S., Dalle, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00126-1 · Cited by 303
Self-citationCombination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Vafaei, S., Zekiy, A. O., Khanamir, R. A., Zaman, B. A., Ghayourvahdat, A., Azimizonuzi, H., & Zamani, M. (2022) · Cancer Cell International · doi:10.1186/s12935-021-02407-8 · Cited by 284
Non-Small-Cell Lung Cancer in 2022: A Review for General Practitioners in Oncology
Mithoowani, H., & Febbraro, M. (2022) · Current Oncology · doi:10.3390/curroncol29030150 · Cited by 281
Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R. M. R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 273
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 273
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Grant, M. J., Herbst, R. S., & Goldberg, S. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00520-1 · Cited by 257
Hot and cold tumors: Immunological features and the therapeutic strategies
Wang, L., Geng, H., Liu, Y., Liu, L., Chen, Y., Wu, F., Liu, Z., Ling, S., Wang, Y., & Zhou, L. (2023) · MedComm · doi:10.1002/mco2.343 · Cited by 261
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
Reckamp, K. L., Redman, M. W., Dragnev, K. H., Minichiello, K., Villaruz, L. C., Faller, B. A., Baghdadi, T. A., Hines, S. J., Everhart, L., Highleyman, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00912 · Cited by 238
Mino-Kenudson, M. A., Schalper, K. A., Cooper, W. A., Đačić, S., Hirsch, F. R., Jain, D., López‐Ríos, F., Tsao, M., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 240
Jassem, J., de Marinis, F., Giaccone, G., Vergnenégre, A., Barrios, C. H., Morise, M., Felip, E., Oprean, C. M., Kim, Y., Andric, Z. G., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.019 · Cited by 222
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 219
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Update 2025: Management of Non‑Small-Cell Lung Cancer
Jeon, H., Wang, S., Song, J., Gill, H., & Cheng, H. (2025) · Lung · doi:10.1007/s00408-025-00801-x · Cited by 229
Mountzios, G., Remón, J., Hendriks, L. E. L., García‐Campelo, R., Rolfo, C. D., Schil, P. E. V., Forde, P. M., Besse, B., Subbiah, V., Reck, M., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00794-7 · Cited by 212
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213
Cook, S., Samuel, V., Meyers, D. E., Stukalin, I., Litt, I., Sangha, R. S., Morris, D. G., Heng, D. Y. C., Pabani, A., Dean, M. L., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.52302 · Cited by 182
Lee, J. B., Kim, H. R., & Ha, S. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 175
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 185
Santoni, M., Rizzo, A., Kucharz, J., Mollica, V., Rosellini, M., Marchetti, A., Tassinari, E., Monteiro, F. S. M., Soares, A., Molina‐Cerrillo, J., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03349-4 · Cited by 151
Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress
Shields, M. D., Marin-Acevedo, J. A., & Pellini, B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321483 · Cited by 145
Dantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 150
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
Singh, N., Temin, S., Baker, S., Blanchard, E. M., Brahmer, J. R., Celano, P., Duma, N., Ellis, P. M., Elkins, I. B., Haddad, R. Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00825 · Cited by 133
Increasing cure rates of solid tumors by immune checkpoint inhibitors
Ma, W., Xue, R., Zhu, Z. G., Farrukh, H., Song, W., Li, T., Zheng, L., & Pan, C.-X. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00372-8 · Cited by 132
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11203200 · Cited by 123
de Miguel‐Pérez, D., Russo, A., Arrieta, O. G., Ak, M., Barrón, F., Gunasekaran, M., Mamindla, P., Lara‐Mejía, L., Peterson, C. B., Er, M. E., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02379-1 · Cited by 121
Makharadze, T., Gogishvili, M., Melkadze, T., Baramidze, A., Giorgadze, D., Penkov, K., Лактионов, К. К., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.03.008 · Cited by 122
Self-citationÖzgüroğlu, M., Kılıçkap, S., Sezer, A., Gümüş, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., Ho, G. F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00329-7 · Cited by 118
Self-citationEmerging evidence and treatment paradigm of non-small cell lung cancer
Liu, S. M., Zheng, M.-M., Pan, Y., Liu, S. M., Li, Y., & Wu, Y.-L. L. C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01436-2 · Cited by 112
Paz-Ares, L. G., Ciuleanu, T., Cobo, M., Bennouna, J., Schenker, M., Cheng, Y., Juan, Ó., Mizutani, H., Lingua, A., Reyes-Cosmelli, F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.014 · Cited by 104
Cho, B. C., Lee, J. S., Wu, Y.-L. L. C., Çiçin, İ., Cobo, M., Ahn, M., Cuppens, K., Veillon, R., Nadal, E., Dias, J. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.08.018 · Cited by 113
Pérol, M., Felip, E., Dafni, U. G., Polito, L., Pal, N., Tsourti, Z., Ton, T. G. N., Merritt, D., Morris, S., Stahel, R. A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.008 · Cited by 105
Alessi, J. V., Elkrief, A., Ricciuti, B., Wang, X., Cortellini, A., Vaz, V. R., Lamberti, G., Frias, R. L., Venkatraman, D., Fulgenzi, C. A. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.091 · Cited by 97
Yin, J., Wu, Y., Yang, X., Gan, L., & Xue, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830631 · Cited by 100
Conforti, F., Pala, L., Pagan, E., Corti, C., Bagnardi, V., Queirolo, P., Catania, C., Pas, T. M. D., & Giaccone, G. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100251 · Cited by 93
Ghiringhelli, F., Bibeau, F., Greillier, L., Fumet, J.-D., Ilie, A., Monville, F., Laugé, C., Catteau, A., Boquet, I., Majdi, A., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104633 · Cited by 91
Schüler, M., Cuppens, K., Plönes, T., Wiesweg, M., Pont, B. D., Hegedűs, B., Köster, J., Mairinger, F. D., Darwiche, K., Paschen, A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02965-0 · Cited by 91
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar, S. R., Shum, E., Grello, C., Lau, S. C. M., & Velcheti, V. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877594 · Cited by 89
Jaiyesimi, I. A., Leighl, N. B., Ismaila, N., Alluri, K. C., Florez, N., Gadgeel, S. M., Masters, G. A., Schenk, E. L., Schneider, B. J., Sequist, L. V. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02746 · Cited by 87
Zhou, Y.-J., Li, G., Wang, J., Liu, M., Wang, Z., Song, Y., Zhang, X., & Wang, X. (2023) · Blood Science · doi:10.1097/bs9.0000000000000149 · Cited by 88
Yang, Z., Gao, J., Zheng, J., Han, J., Li, A., Liu, G., Sun, Y., Zhang, J., Chen, G., Xu, R., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01762-y · Cited by 88
Akinboro, O., Larkins, E., Pai-Scherf, L. H., Mathieu, L. N., Ren, Y., Cheng, J., Fiero, M. H., Fu, W., Bi, Y., Kalavar, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3844 · Cited by 85
Zhang, M., Fan, Y., Nie, L., Wang, G., Sun, K., & Cheng, Y. (2022) · CHEST Journal · doi:10.1016/j.chest.2021.12.656 · Cited by 82
Liu, Z., Zhu, Y., Xie, H., & Zou, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1077468 · Cited by 84
Preet, R., Islam, M. A., Shim, J., Rajendran, G., Mitra, A., Vishwakarma, V., Kutz, C., Choudhury, S., Pathak, H. B., Dai, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58553-4 · Cited by 82
The emerging roles of NGS in clinical oncology and personalized medicine
Hussen, B. M., Abdullah, S. T., Salihi, A. B., Sabir, D. K., Sidiq, K. R., Rasul, M. F., Hidayat, H. J., Ghafouri‐Fard, S., Taheri, M. N., & Jamali, E. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153760 · Cited by 87
Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerations
Chen, X., Chen, L., Peng, X., Deng, L., Wang, Y., Li, J.-J., Guo, D., & Niu, X. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101851 · Cited by 80
Zhou, C., Chen, G., Huang, Y., Zhou, J., Lin, L., Feng, J., Wang, Z., Shu, Y., Shi, J., Hu, Y., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.12.017 · Cited by 76
Self-citationReady, N., Audigier-Valette, C., Goldman, J. W., Felip, E., Ciuleanu, T., Campelo, M. R. G., Jao, K., Barlési, F., Bordenave, S., Rijavec, E., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006127 · Cited by 77
Self-citationPatterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
Yang, F., Shay, C., Abousaud, M. I., Tang, C., Li, Y., Qin, Z. S., Saba, N. F., & Teng, Y. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02568-y · Cited by 76
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 75
Ohri, N., Jolly, S., Cooper, B. T., Kabarriti, R., Bodner, W. R., Klein, J., Guha, C., Shankar, V., Shum, E., Sabari, J. K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00627 · Cited by 70
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 73
Wang, L., Luo, Y., Ren, S., Zhang, Z., Xiong, A., Su, C., Zhou, J., Yu, X., Hu, Y., Zhang, X., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.10.014 · Cited by 68
Olivares-Hernández, A., Portillo, E. G.-D., Tamayo-Velasco, Á., Figuero-Pérez, L., Zhilina-Zhilina, S., Fonseca‐Sánchez, E., & Miramontes‐González, J. P. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4218 · Cited by 68
Neal, J. W., Pavlakis, N., Kim, S., Goto, Y., Lim, S. M., Mountzios, G., Fountzilas, E., Mochalova, A. S., Christoph, D. C., Bearz, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02166 · Cited by 67
Wang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K., & Zhang, J. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00979-8 · Cited by 65
Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance
Deng, J., Zhou, M. L., Liao, T., Kuang, W., Xia, H., Yin, Z., Tan, Q., Li, Y., Song, S., Zhou, E., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818453 · Cited by 63
Peters, S., Paz-Ares, L. G., Herbst, R. S., & Reck, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004863 · Cited by 60
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 68
Chu, X., Niu, L., Xiao, G., Peng, H., Deng, F., Liu, Z., Wu, H., Yang, L., Tan, Z., Li, Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875488 · Cited by 58
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 62
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 54
Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy
Lee, C. K., Atibalentja, D. F., Yao, L. E., Park, J., Kuruvilla, S. P., & Felsher, D. W. (2022) · Nanotheranostics · doi:10.7150/ntno.65544 · Cited by 55
Immunosenescence, inflammaging, and cancer immunotherapy efficacy
Rodriguez, J. E., Naigeon, M., Goldschmidt, V., Dugage, M. R., Seknazi, L., Danlos, F., Champiat, S., Marabelle, A., Michot, J., Massard, C., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2098718 · Cited by 55
Teng, Y.-S., & Yu, S. (2023) · Current Oncology · doi:10.3390/curroncol30070498 · Cited by 57
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 52
Bischoff, P., Reck, M., Overbeck, T. R., Christopoulos, P., Rittmeyer, A., Lüders, H., Kollmeier, J., Kulhavy, J., Kemper, M., Reinmuth, N., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.12.015 · Cited by 55
Wang, J., Lu, S., Yu, X., Hu, Y., Zhao, J., Sun, M., Yu, Y., Hu, C., Yang, K., Song, Y., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103727 · Cited by 54
Rybkin, I. I., & Gadgeel, S. M. (2022) · Medical radiology · doi:10.1007/174_2022_313 · Cited by 51
Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy
Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 51
Sharma, A., Alexander, G., Chu, J. H., Markopoulos, A., Maloul, G., Ayub, M. T., Fidler, M. J., & Okwuosa, T. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032620 · Cited by 49
Erasha, A. M., El-Gendy, H. F., Aly, A. S., Fernández‐Ortiz, M., & Sayed, R. K. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062716 · Cited by 52
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 47
Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung
Santos, E. S., & Rodríguez, E. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.06.002 · Cited by 46
Cancer Immunotherapy and Delivery System: An Update
Yang, M. J., Olaoba, O. T., Zhang, C., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081630 · Cited by 46
Liu, S., Dong, S., Yang, X., Liao, R.-Q., Jiang, B., Wang, Q., Ben, X., Qiao, G., Lin, J., Yan, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01700-4 · Cited by 48
Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, C., John, T., & Wong, A. N. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1489977 · Cited by 46
Liu, S., Gao, W., Ning, Y., Zou, X., Zhang, W., Zeng, L., & Liu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.908173 · Cited by 46
Arasanz, H., Bocanegra, A., Morilla, I., Fernández‐Irigoyen, J., Martínez-Aguillo, M., Teijeira, L., Garnica, M., Blanco, E., Chocarro, L., Ausín, K., et al. (2022) · Cancers · doi:10.3390/cancers14163846 · Cited by 47
Wang, Y., Han, H., Zhang, F., Lv, T., Zhan, P., Ye, M., Song, Y., & Liu, H. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01832-4 · Cited by 44
Immunotherapy in NSCLC Patients with Brain Metastases
Buriolla, S., Pelizzari, G., Corvaja, C., Alberti, M., Targato, G., Bortolot, M., Torresan, S., Cortiula, F., Fasola, G., & Follador, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137068 · Cited by 47
Metadata
- Authors
- Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Gao, B., Li, S., Lee, S., McGuire, K., Chen, C.-I., Makharadze, T., Paydas, S., Nechaeva, M., Seebach, F., Weinreich, D. M., Yancopoulos, G. D., Gullo, G., Lowy, I., & Rietschel, P.
- Affiliations
- Başkent University (TR)
- Istanbul Medeniyet University (TR)
- Dnipro State Medical University (UA)
- Istanbul University-Cerrahpaşa (TR)
- University of Wollongong (AU)
- Chulalongkorn University (TH)
- Columbia University Irving Medical Center (US)
- Regeneron (United States) (US)
- Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser (RU)
- Corresponding author
- Sezer, Ahmet
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 397
- Issue
- 10274
- Pages
- 592-604
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3129022890
- Cited by
- 789
- References
- 31
- Citations by year
- 2026: 52 · 2025: 133 · 2024: 164 · 2023: 197 · 2022: 167 · 2021: 74
- FWCI
- 54.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- Trakya University's Institutional Open Access System (Trakya University) (submittedVersion)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- cemiplimab, non-small cell lung cancer, PD-L1 expression, PD-1 inhibitors, first-line therapy, platinum-based chemotherapy, overall survival, progression-free survival, immune checkpoint inhibitors, treatment crossover, adverse events, immune-related adverse events, immunotherapy versus chemotherapy, never smokers
- MeSH terms
- Pemetrexed, Antineoplastic Agents, Immunological, Progression-Free Survival, Immune Checkpoint Inhibitors, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Humans, Lung Neoplasms, Male, Middle Aged, Survival Rate, Carboplatin, Paclitaxel, B7-H1 Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
